The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market

Ricardo Titze-de-Almeida, Catherine David & Simoneide Souza Titze-de-Almeida. Pharmaceutical Research. 2017.
“KRAS-LODER made KRAS a druggable anticancer target. New drugs also targeting this oncogene are now in test and may represent future competitors of KRAS-LODER. KRAS-LODER is the only RNAi-based drug that provides a sustained release of siRNA into the tumor region thanks to a well-known biodegradable PLGA polymer, approved by FDA for drug delivery.
This siRNA represents a hopeful strategy against advanced pancreatic cancer…. Taking the aggressive behavior of pancreatic tumor cells, KRAS-LODER is a promising anticancer therapy.
Results of a phase 1/2a was positive in a relatively small number of patients, so we must wait for an ongoing phase 2 study that is testing KRAS-LODER (2.8 mg) plus standard chemotherapy for patients with unresectable advanced pancreatic cancer”
Read More
 

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email